Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

JAK2 -V617F-Driven Myeloproliferative Neoplasms (MPN) Are Initiated By a Subset of HSCs Marked By High Expression of the Vwf-GFP Reporter Gene

Quentin Kimmerlin, Marc Usart, Tiago Fonseca, Hui Hao-Shen, Radek C. Skoda

Blood (2024) 144 (Supplement 1): 751.

https://doi.org/10.1182/blood-2024-206909

Published: 2024

Journal Articles

Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2 -V617F–positive myeloproliferative neoplasms

Marc Usart, Jan Stetka, Damien Luque Paz, Nils Hansen, Quentin Kimmerlin, Tiago Almeida Fonseca, Melissa Lock, Lucia Kubovcakova, Riikka Karjalainen, Hui Hao-Shen, Anastasiya Börsch, Athimed El Taher, Jessica Schulz, Jean-Christophe Leroux, Stefan Dirnhofer, Radek C. Skoda

Blood (2024) 143 (24): 2490–2503.

https://doi.org/10.1182/blood.2023020270

Published: 2024

Includes: Supplemental data

Journal Articles

Cellular Barcoding of JAK2 -V617F Hematopoietic Stem Cells Reveals No Substantial Preferences in the Contribution of Individual Stem Cell Clones to Erythroid Versus Megakaryocytic Lineages

Marc Usart, Tiago Almeida, Julien Roux, Athimed El Taher, Riikka Karjalainen, Quentin Kimmerlin, Shivam Rai, Hui Hao-Shen, Radek C. Skoda

Blood (2023) 142 (Supplement 1): 859.

https://doi.org/10.1182/blood-2023-181695

Published: 2023

Journal Articles

Zinpentraxin Alfa Reduces Myelofibrosis in a JAK2 -V617F Mouse Model of Myeloproliferative Neoplasms

Shivam Rai, Hui Hao-Shen, Stefan Dirnhofer, Julien Roux, Rajbharan Yadav, Anamarija Pfeiffer, Jakob Vowinckel, Audrey Arjomandi, Brian Higgins, Lyrialle Han, Kerstin Trunzer, Pontus Lundberg, Radek C. Skoda

Blood (2023) 142 (Supplement 1): 1787.

https://doi.org/10.1182/blood-2023-186631

Published: 2023

Journal Articles

Iron is a modifier of the phenotypes of JAK2 -mutant myeloproliferative neoplasms

Blood (2023) 141 (17): 2127–2140.

https://doi.org/10.1182/blood.2022017976

Published: 2023

Includes: Supplemental data

Journal Articles

Disrupting the Socs2 -Mediated Negative Feedback to JAK-STAT Signaling Boosts Molecular Responses Induced By Interferon-α in a Mouse Model of Myeloproliferative Neoplasms

Marc Usart, Cédric B. Stoll, Riikka Karjalainen, Hui Hao-Shen, Radek C. Skoda

Blood (2022) 140 (Supplement 1): 9580–9581.

https://doi.org/10.1182/blood-2022-169232

Published: 2022

Journal Articles

Combination of 5-Azacytidine and Pegifna Is Able to Overcome Resistance in JAK2 -V617F Positive MPN with Loss of Dnmt3a

Melissa Lock, Damien Luque Paz, Nils Hansen, Tiago Almeida Fonseca, MARC Usart, Shivam Rai, Hui Hao-Shen, Gabriele Mild, Stephan Dirnhofer, Radek C. Skoda, Jan Stetka

Blood (2022) 140 (Supplement 1): 3876–3877.

https://doi.org/10.1182/blood-2022-167002

Published: 2022

Journal Articles

The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)

Shivam Rai, Jan Stetka, MARC Usart, Hui Hao-Shen, Young Park, Remie Houston, Anthony R. Martinez Benitez, Matthew Wereski, Emily Guzzardi, Sonali Persaud, Hailey Ramzan, Alan Futran, Charley Xu, Jeremy Greenwood, Sayan Mondal, Craig Masse, Ross L. Levine, Radek C. Skoda, Andrew Dunbar

Blood (2022) 140 (Supplement 1): 6722–6723.

https://doi.org/10.1182/blood-2022-162621

Published: 2022

Journal Articles

Inhibiting Glutamine Metabolism with CB-839 Reduces Erythrocytosis in MPN Mice

MARC Usart, Shivam Rai, Nils Hansen, Alexandre Guy, Jan Stetka, Hui Hao-Shen, Tata Nageswara Rao, Radek C. Skoda

Blood (2021) 138 (Supplement 1): 3585.

https://doi.org/10.1182/blood-2021-150321

Published: 2021

Journal Articles

BTG1 Mutation Promotes Aggressive Lymphoma Development By Lowering the Threshold to MYC Activation and Generating "Super-Competitor" B Cells

Blood (2021) 138 (Supplement 1): 359.

https://doi.org/10.1182/blood-2021-149921

Published: 2021

Journal Articles

JAK2 -V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality

Tata Nageswara Rao, Nils Hansen, Jan Stetka, Damien Luque Paz, Milena Kalmer, Julian Hilfiker, Max Endele, Nouraiz Ahmed, Lucia Kubovcakova, Margareta Rybarikova, Hui Hao-Shen, Florian Geier, Christian Beisel, Stefan Dirnhofer, Timm Schroeder, Tim H. Brümmendorf, Dominik Wolf, Steffen Koschmieder, Radek C. Skoda

Blood (2021) 137 (16): 2139–2151.

https://doi.org/10.1182/blood.2020005563

Published: 2021

Includes: Supplemental data

Journal Articles

Loss of Dnmt3a Confers Resistance to Pegifnα in JAK2 -V617F Mouse Model

Jan Stetka, Nils Hansen, Lucia Kubovcakova, Hui Hao-Shen, Stefan Dirnhofer, Radek C. Skoda

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140548

Published: 2020

Journal Articles

JAK2 -mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms

Blood (2019) 134 (21): 1832–1846.

https://doi.org/10.1182/blood.2019000162

Published: 2019

Includes: Supplemental data

Journal Articles

IL-1β Secreted from Mutant Cells Carrying JAK2- V617Ffavors Early Clonal Expansion and Promotes MPN Disease Initiation and Progression

Shivam Rai, Nils Hansen, Hui Hao-Shen, Stefan Dirnhofer, Nageswara Rao Tata, Radek C. Skoda

Blood (2019) 134 (Supplement_1): 307.

https://doi.org/10.1182/blood-2019-129800

Published: 2019

Journal Articles

SIRT3 Is a Novel Metabolic Driver of and Therapeutic Target for Chemotherapy Resistant Dlbcls

Meng Li, PhD, Ying-Ling Chiang, PhD, Costas Lyssiotis, PhD, Matthew Teater, PhD, Hao Shen, MD, Ling Wang, MS, Jun Young Hong, BS, Hui Jin, PhD, Cihangir Duy, PhD, Sucharita Mistry, PhD, Leandro Cerchietti, MD, Justin Cross, PhD, Lewis Cantley, MD, Hening Lin, PhD, Ari Melnick, MD

Blood (2017) 130 (Supplement 1): 643.

https://doi.org/10.1182/blood.V130.Suppl_1.643.643

Published: 2017

Journal Articles

Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms

Sara C. Meyer, MD PhD, Nilabh Ghosh, MSc, Simona Stivala, PhD, Anne Baerenwaldt, PhD, Hui Hao-Shen, Stefan Dirnhofer, MD, Matthias S. Dettmer, MD, Cédric Simillion, PhD, Sophia Chiu, MSc, Matthew Keller, MSc, Maria Kleppe, PhD, Morgane Hilpert, PhD, Andreas S. Buser, MD, Jakob R. Passweg, MDMS, Thomas Radimerski, PhD, Radek C. Skoda, MD, Ross L. Levine, MD

Blood (2017) 130 (Supplement 1): 381.

https://doi.org/10.1182/blood.V130.Suppl_1.381.381

Published: 2017

Journal Articles

JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis

Jean Grisouard, Sai Li, Lucia Kubovcakova, Tata Nageswara Rao, Sara C. Meyer, Pontus Lundberg, Hui Hao-Shen, Vincent Romanet, Masato Murakami, Thomas Radimerski, Stephan Dirnhofer, Radek C. Skoda

Blood (2016) 128 (6): 839–851.

https://doi.org/10.1182/blood-2015-12-689216

Published: 2016

Includes: Supplemental data

Journal Articles

Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2 -V617F mouse model of MPN

Jean Grisouard, Takafumi Shimizu, Adrian Duek, Lucia Kubovcakova, Hui Hao-Shen, Stephan Dirnhofer, Radek C. Skoda

Blood (2015) 125 (13): 2131–2140.

https://doi.org/10.1182/blood-2014-08-594572

Published: 2015

Includes: Supplemental data

Journal Articles

JAK2V617F and Loss of Ezh2 in Hematopoietic Cells Contribute Synergistically to Myeloproliferative Neoplasm Initiation Potential, and Accelerate Progression of Disease

Takafumi Shimizu, PhD, Hui Hao-Shen, Lucia Kubovcakova, PhD, Pontus Lundberg, PhD, Stephan Dirnhofer, Stuart H. Orkin, MD, Jean Grisouard, PhD, Yukiko Shimizu, Annalisa Pianta, PhD, Barbara Szczerba, Ronny Nienhold, Radek C. Skoda, MD

Blood (2014) 124 (21): 158.

https://doi.org/10.1182/blood.V124.21.158.158

Published: 2014

Journal Articles

Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2 -V617F–driven mouse model of MPNs

Adrian Duek, Pontus Lundberg, Takafumi Shimizu, Jean Grisouard, Axel Karow, Lucia Kubovcakova, Hui Hao-Shen, Stephan Dirnhofer, Radek C. Skoda

Blood (2014) 123 (25): 3943–3950.

https://doi.org/10.1182/blood-2013-07-514208

Published: 2014

NARROW

JAK2 -V617F-Driven Myeloproliferative Neoplasms (MPN) Are Initiated By a Subset of HSCs Marked By High Expression of the Vwf-GFP Reporter Gene

Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2 -V617F–positive myeloproliferative neoplasms

Cellular Barcoding of JAK2 -V617F Hematopoietic Stem Cells Reveals No Substantial Preferences in the Contribution of Individual Stem Cell Clones to Erythroid Versus Megakaryocytic Lineages

Zinpentraxin Alfa Reduces Myelofibrosis in a JAK2 -V617F Mouse Model of Myeloproliferative Neoplasms

Iron is a modifier of the phenotypes of JAK2 -mutant myeloproliferative neoplasms

Disrupting the Socs2 -Mediated Negative Feedback to JAK-STAT Signaling Boosts Molecular Responses Induced By Interferon-α in a Mouse Model of Myeloproliferative Neoplasms

Combination of 5-Azacytidine and Pegifna Is Able to Overcome Resistance in JAK2 -V617F Positive MPN with Loss of Dnmt3a

The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)

Inhibiting Glutamine Metabolism with CB-839 Reduces Erythrocytosis in MPN Mice

BTG1 Mutation Promotes Aggressive Lymphoma Development By Lowering the Threshold to MYC Activation and Generating "Super-Competitor" B Cells

JAK2 -V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality

Loss of Dnmt3a Confers Resistance to Pegifnα in JAK2 -V617F Mouse Model

JAK2 -mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms

IL-1β Secreted from Mutant Cells Carrying JAK2- V617Ffavors Early Clonal Expansion and Promotes MPN Disease Initiation and Progression

SIRT3 Is a Novel Metabolic Driver of and Therapeutic Target for Chemotherapy Resistant Dlbcls

Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms

JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis

Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2 -V617F mouse model of MPN

JAK2V617F and Loss of Ezh2 in Hematopoietic Cells Contribute Synergistically to Myeloproliferative Neoplasm Initiation Potential, and Accelerate Progression of Disease

Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2 -V617F–driven mouse model of MPNs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only